SUN Pharmaceutical Industries Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: SUN Pharmaceutical Industries Limited Pharmaceutical Export Portfolio Dataset — 118 Products, $979.8M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

SUN Pharmaceutical Industries Limited — Pharmaceutical Exporter Profile (2026) | 118 Products, $979.8M Trade | TransData Nexus

SUN Pharmaceutical Industries Limited

Indian Pharmaceutical Exporter · Gastrointestinal Specialist · $979.8M Total Trade · DGFT Verified

SUN Pharmaceutical Industries Limited is an Indian pharmaceutical exporter with a total trade value of $979.8M across 118 products in 25 therapeutic categories. Based on 23,420 verified export shipments from Indian Customs (DGFT) records, SUN Pharmaceutical Industries Limited is the #1 Indian exporter in 24 products including Strip, Esomeprazole, Magnesium. Top exports include Strip ($125.7M), Esomeprazole ($85.6M), Magnesium ($75.5M).

SUN Pharmaceutical Industries Limited — Export Portfolio & Destination Treemap

SUN Pharmaceutical Industries Limited pharmaceutical export portfolio — 118 products across 25 therapeutic categories. Source: Indian Customs (DGFT).

Who is SUN Pharmaceutical Industries Limited? — Company Overview & Market Position

Sun Pharmaceutical Industries Limited, established in 1983, is a leading Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company specializes in the development, manufacturing, and marketing of a diverse range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). Sun Pharma's extensive product portfolio encompasses generics, branded generics, specialty medications, over-the-counter (OTC) products, and antiretrovirals, catering to various therapeutic areas such as neuropsychiatry, cardiology, gastroenterology, and oncology.

As of the latest available data, Sun Pharma employs over 43,000 individuals globally. The company's shares are publicly traded on the Bombay Stock Exchange (BSE) under the ticker symbol 524715 and on the National Stock Exchange of India (NSE) under the ticker symbol SUNPHARMA. The promoter holding stands at 54.47%, with the remaining 45.53% held by public shareholders. For more information, visit their official website at sunpharma.com.

What Does SUN Pharmaceutical Industries Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Strip$125.7M

Product Portfolio — Top 30 by Export Value

SUN Pharmaceutical Industries Limited exports 118 pharmaceutical products across 25 therapeutic categories. Market leader (#1 exporter) in 24 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Strip	Medical Devices & Diagnostics	$125.7M	2,513	60.9%	1
2	Esomeprazole	Gastrointestinal	$85.6M	1,712	18.1%	1
3	Magnesium	Vitamins & Supplements	$75.5M	1,511	20.2%	1
4	Calcium	Vitamins & Supplements	$57.0M	1,558	6.4%	4
5	Omeprazole	Gastrointestinal	$53.6M	1,073	8.4%	1
6	Atorvastatin	Cardiovascular	$32.8M	1,299	3.0%	8
7	Sertraline	CNS & Psychiatric	$32.1M	642	5.7%	3
8	Pantoprazole	Gastrointestinal	$31.0M	776	2.3%	4
9	Rosuvastatin	Cardiovascular	$30.9M	619	6.7%	5
10	Citalopram	CNS & Psychiatric	$23.0M	463	9.0%	3
11	Ciprofloxacin	Antibiotics	$21.4M	427	6.8%	2
12	Cefuroxime	Advanced Antibiotics	$16.8M	336	13.0%	1
13	Temozolomide	Advanced Oncology	$15.6M	330	62.4%	1
14	Clarithromycin	Antibiotics	$15.4M	309	15.7%	2
15	Sodium	Nutritional Supplements	$15.4M	309	4.3%	3
16	Amoxicillin	Antibiotics	$15.3M	307	2.5%	5
17	Gliclazide	Advanced Diabetes Medications	$15.1M	470	5.0%	3
18	Gabapentin	CNS & Psychiatric	$11.7M	234	1.4%	13
19	Ofloxacin	Advanced Antibiotics	$11.2M	224	3.4%	4
20	Mesalamine	Gastrointestinal	$11.1M	222	0.8%	2
21	Meropenem	Advanced Antibiotics	$10.8M	216	4.6%	1
22	Escitalopram	CNS & Psychiatric	$10.7M	293	5.5%	6
23	Cephalexin	Antibiotics	$10.6M	294	3.0%	4
24	Simvastatin	Cardiovascular	$10.4M	516	8.2%	4
25	Irbesartan	Cardiovascular	$8.3M	298	7.9%	4
26	Ezetimibe	Lipid & Metabolism	$7.9M	191	1.5%	6
27	Budesonide	Respiratory	$7.8M	166	4.1%	2
28	Doxorubicin	Oncology	$7.8M	156	11.1%	1
29	Fexofenadine	Antihistamines & Allergy	$7.7M	154	7.0%	5
30	Clopidogrel	Cardiovascular	$7.5M	150	3.0%	11

SUN Pharmaceutical Industries Limited exports 118 pharmaceutical products across 25 therapeutic categories with a total export value of $979.8M. The company is the #1 Indian exporter in 24 products: Strip, Esomeprazole, Magnesium, Omeprazole, Cefuroxime and 3 more. The top category is Gastrointestinal (18.9% of portfolio), followed by Medical Devices & Diagnostics (13.7%), reflecting a diversified portfolio where the top 5 products account for only 40.6% of total value.

Showing top 30 of 118 products. Contact us for complete data.

SUN Pharmaceutical Industries Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Sun Pharmaceutical Industries Limited operates a global network of manufacturing facilities, with 41 plants strategically located across India, the United States, and other international markets. These facilities are equipped to produce a wide array of pharmaceutical products, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company's manufacturing capabilities are supported by a dedicated team of over 2,900 R&D professionals, enabling the development of complex formulations and specialty products.

3Key Leadership

The leadership team at Sun Pharmaceutical Industries Limited is headed by Managing Director and Executive Chairman, Mr. Dilip S. Shanghvi. Mr. Aalok D. Shanghvi serves as the Chief Operating Officer and Head of Global Generics Research & Development. The Chief Financial Officer is Ms. Jayashree Satagopan, who also holds the position of Executive Vice President. Other key executives include Mr. Dheeraj Prasad Sinha, Executive Vice President and Chief Information Officer, and Mr. Suresh Kumar Rai, Chief Human Resources Officer.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does SUN Pharmaceutical Industries Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Sun Pharmaceutical Industries Limited has a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. In the U.S., the company has been operational since 1996, offering a range of generics, branded generics, and OTC products. Sun Pharma's U.S. headquarters are located in Princeton, New Jersey, with distribution and customer service teams across the country. In June 2024, the U.S. Food and Drug Administration (FDA) issued a warning letter to Sun Pharma's facility in Dadra and Nagar Haveli, India, citing violations of Current Good Manufacturing Practice (CGMP) regulations. The company has also received approvals from the European Medicines Agency (EMA) and other regulatory bodies for various products, facilitating its market access in these regions.

2Emerging Markets

Sun Pharmaceutical Industries Limited has expanded its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company's products are available in over 100 countries, with a strong presence in regions such as Brazil, Mexico, Russia, Romania, and South Africa. Sun Pharma's commitment to improving access to medicines is evident through its participation in the World Health Organization's (WHO) prequalification program, which enables the company to supply quality-assured medicines to low- and middle-income countries.

SUN Pharmaceutical Industries Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Sun Pharmaceutical Industries Limited's facilities are registered with the U.S. Food and Drug Administration (FDA), allowing the company to manufacture and distribute pharmaceutical products in the United States. The company has filed numerous Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs) with the FDA, facilitating the approval of generic formulations. However, in June 2024, the FDA issued a warning letter to Sun Pharma's facility in Dadra and Nagar Haveli, India, citing violations of Current Good Manufacturing Practice (CGMP) regulations. The company has since taken corrective actions to address the identified issues and maintain compliance with FDA standards.

2WHO & EU GMP

Sun Pharmaceutical Industries Limited's manufacturing facilities adhere to the World Health Organization's (WHO) Good Manufacturing Practices (GMP) and the European Union's GMP standards. The company's commitment to quality is demonstrated through its participation in the WHO prequalification program, which ensures that its products meet international quality standards. Additionally, Sun Pharma has obtained EU GMP certificates for its facilities, enabling the company to supply pharmaceutical products to European markets.

CDSCO & Indian Regulatory

SUN Pharmaceutical Industries Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Sun Pharmaceutical Industries Limited operates in a highly competitive pharmaceutical market, facing competition from both multinational and domestic companies. In the generic pharmaceutical sector, Sun Pharma competes with companies such as Teva Pharmaceutical Industries, Sandoz (a division of Novartis), and Mylan. In the specialty pharmaceutical segment, competitors include Bristol-Myers Squibb, Merck & Co., and Novartis. Sun Pharma's focus on complex formulations and specialty products differentiates it from competitors, allowing the company to capture market share in niche therapeutic areas.

2Key Differentiators

Sun Pharmaceutical Industries Limited's key differentiators include its extensive product portfolio, which spans generics, branded generics, specialty medications, and over-the-counter products. The company's strong research and development capabilities, supported by a global network of R&D centers and a dedicated team of over 2,900 professionals, enable the development of complex formulations and specialty products. Sun Pharma's commitment to quality is demonstrated through its adherence to international manufacturing standards, including WHO and EU GMP certifications. Additionally, the company's strategic acquisitions, such as Taro Pharmaceuticals, have enhanced its presence in key markets like the United States.

Strategic Position

Buyer Due Diligence Brief — Evaluating SUN Pharmaceutical Industries Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Sun Pharmaceutical Industries Limited has a strong track record as a pharmaceutical supplier, with a diverse product portfolio and a global presence in over 100 countries. The company's manufacturing facilities adhere to international quality standards, including WHO and EU GMP certifications, ensuring the safety and efficacy of its products. Sun Pharma's commitment to innovation is demonstrated through its substantial investment in research and development, with a dedicated team of over 2,900 professionals. The company's strategic acquisitions, such as Taro Pharmaceuticals, have enhanced its capabilities and market reach, particularly in the United States. Sun Pharma's consistent focus on quality, innovation, and global expansion positions it as a reliable and competitive supplier in the pharmaceutical industry.

2Certifications to Verify

Importers should verify the following certifications when sourcing products from Sun Pharmaceutical Industries Limited:

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — SUN Pharmaceutical Industries Limited

How many pharmaceutical products does SUN Pharmaceutical Industries Limited export from India?

SUN Pharmaceutical Industries Limited exports 118 pharmaceutical products across 25 therapeutic categories. The top exports are Strip ($125.7M), Esomeprazole ($85.6M), Magnesium ($75.5M), Calcium ($57.0M), Omeprazole ($53.6M). Total export value is $979.8M.

What is SUN Pharmaceutical Industries Limited's total pharmaceutical export value?

SUN Pharmaceutical Industries Limited's total pharmaceutical export value is $979.8M, based on 23,420 verified shipments recorded in Indian Customs (DGFT) data.

In which products is SUN Pharmaceutical Industries Limited the #1 Indian exporter?

SUN Pharmaceutical Industries Limited is the #1 Indian exporter in 24 products: Strip (60.9% market share), Esomeprazole (18.1% market share), Magnesium (20.2% market share), Omeprazole (8.4% market share), Cefuroxime (13.0% market share), Temozolomide (62.4% market share), Meropenem (4.6% market share), Doxorubicin (11.1% market share).

What therapeutic categories does SUN Pharmaceutical Industries Limited cover?

SUN Pharmaceutical Industries Limited exports across 25 therapeutic categories. The largest are Gastrointestinal (18.9%, 8 products), Medical Devices & Diagnostics (13.7%, 3 products), Vitamins & Supplements (13.5%, 2 products).

Get Full SUN Pharmaceutical Industries Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.